Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 39.78M P/E - EPS this Y 64.70% Ern Qtrly Grth -
Income -51.85M Forward P/E -3.29 EPS next Y 82.10% 50D Avg Chg -17.00%
Sales 103k PEG - EPS past 5Y - 200D Avg Chg -49.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -85.00%
Recommedations 1.70 Quick Ratio 0.27 Shares Outstanding 34.99M 52W Low Chg 25.00%
Insider Own 7.87% ROA -349.18% Shares Float 28.74M Beta 0.93
Inst Own 14.43% ROE - Shares Shorted/Prior 3.74M/3.35M Price 2.30
Gross Margin - Profit Margin - Avg. Volume 236,840 Target Price 17.25
Oper. Margin -169,483.33% Earnings Date May 13 Volume 609,269 Change -8.73%
About Checkpoint Therapeutics, Inc.

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is also developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Checkpoint Therapeutics, Inc. News
03/24/24 Checkpoint Therapeutics Full Year 2023 Earnings: Misses Expectations
03/22/24 Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
03/18/24 Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
01/29/24 Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market
01/11/24 Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference
12/19/23 Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Profit Outlook
12/18/23 UPDATE 1-US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy
12/18/23 U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer
12/11/23 3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023
12/05/23 Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance
11/13/23 Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
10/18/23 Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer
10/02/23 Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds
09/21/23 Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference
09/06/23 Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
08/14/23 Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
08/14/23 Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
07/31/23 Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
07/27/23 Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
06/28/23 Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing
CKPT Chatroom

User Image DameWave Posted - 7 hours ago

@1Timothy617 And from $TGTX's most recent 10-K page 12: https://ir.tgtherapeutics.com/static-files/e3dce0f3-8f56-4565-a937-29808661ed2e So you own both $CKPT and $TGTX but don't read the reports?

User Image DameWave Posted - 7 hours ago

$FBIO $CKPT $TGTX NO! "Effective September 30, 2023, the Company and TGTX agreed to mutually terminate these collaborations, with full rights reverting back to us" Want more proof? Checkpoint writes it clearly and repeatedly, time and time again, on page 2, 3, 4, 5, 10, 12, 43, 50, F-11, F-16, F-17, Exhibit 10.12.2, Exhibit 10.12.3. https://ir.checkpointtx.com/financial-information/financial-results https://content.equisolve.net/checkpointtx/sec/0001410578-24-000283/for_pdf/ckpt-20231231xex10d122.htm https://content.equisolve.net/checkpointtx/sec/0001410578-24-000283/for_pdf/ckpt-20231231xex10d123.htm "As a holder of both"... Do your homework then!

User Image 1Timothy617 Posted - 8 hours ago

$CKPT would love to see a combo merger/all stock BO by TG @ 2:1 CK:TG shares As a holder of both, think this would be mutually beneficial play, and best value for CK/TG/FBIO

User Image 1Timothy617 Posted - 9 hours ago

$CKPT

User Image kiwiSurfer Posted - 9 hours ago

$CKPT down 9 % on high volume No Bueno here comes $1.18.

User Image mikeywo Posted - 10 hours ago

$CKPT come on James. Where you at ?

User Image SWICH Posted - 10 hours ago

$CKPT Around 3M shares traded Off Exchange thus far in the month of April. Another million or so to complete the HCW sale of the Armistice shares being offloaded.

User Image T_rader Posted - 12 hours ago

$CKPT looks like pushing it to $1.39…ready on the trigger

User Image Hereinbama35 Posted - 14 hours ago

$CKPT Does anyone here hold out any hope any more? Asking for a friend.

User Image neofeudal Posted - 14 hours ago

$CHRS $CKPT If I might further observe...CHRS has a PD-1 inhibitor (Toripalimab) and CKPT has a PD-L1 inhibitor (Cosibelimab). These two drug categories are possibly complementary, (molecular-cancer.biomedcent...), so a merger would be accretive re: the core product offering and potential. What a powerhouse of potential that would make.

User Image SWICH Posted - 16 hours ago

$CKPT $CHRS I may be delusional but my research and experience have me convinced that this deal is happening. Both stocks have been kept in relatively close alignment to maintain what I believe are the agreed-to MC valuations and SP premium. The incentive for all SH in this all-equity, hedge fund-brokered deal is the synergies and deep I/O pipeline, infrastructure that would be created in the combined company. Unlike the SURF deal, the CHRS SP has been brought down in advance of the deal so that SH from both entities can benefit from the immediate climb up after the deal is announced. Time will tell...

User Image 1Timothy617 Posted - 1 day ago

@TheGunnerAB that’s how I read the annual request to increase approved outstanding shares. a request to bump the approved from 175m to 190m, while there are only ~155m current outstanding doesn’t quite have much logic if a near term exit and CF+ here is the plan Why need another 500m-1b+ of potential cash raise (depending on SP) if not with the idea of potential acquisitions under the TG brand? Imo, if he wants to take that route, we should just buy the sister co, $CKPT. Cosi has huge potential in the NSCLC space, with keytruda making 25b+/yr, and PD-L1’s having quite a few applications across oncology

User Image T_rader Posted - 1 day ago

$CKPT entry incoming….trying to be patient as I’ve lost this game before on this ticker

User Image baubee Posted - 1 day ago

$CKPT little bit up, even more down.. rinse, repeat daily. You'd think they'd provide some updates on the CRL resolution but nope, this company/ticker's a real turd.

User Image LongBallBarn Posted - 1 day ago

@pumaa Yeh $TENX I have a position basis like 8 bucks but gonna add more soon I think...high risk maybe but possible huge reward...like $VTVT too but own that at like 9 and it already spiked to 25.. $CKPT and $GERN too

User Image DameWave Posted - 1 day ago

$XBI Even though $FBIO is by far my largest holding (read old posts), and they are the largest owner of $CKPT, and the fact that if I buy shares in $FBIO, I get the entire portfolio for free except for $DERMf ($FBIO owns 53%) and that includes $CKPT I bought shares in $CKPT today... Messy introduction, but thought I'd explain why in a longer series of posts sometime this week.

User Image kiwiSurfer Posted - 2 days ago

$CKPT going to re-enter at just above $1…dive dive dive down periscope!!!

User Image DameWave Posted - 2 days ago

@Radcon2017 $CKPT is also a diamond in the future (guessing buyout within a year at the most).

User Image DameWave Posted - 2 days ago

$CKPT I'll try one last time to post this... $FBIO

User Image MSBio Posted - 2 days ago

$CKPT Don't understand what the manufacturing issues are, facilities, equipment, trainings, documentation? Should they be addressed already?

User Image SWICH Posted - 3 days ago

$CKPT don't sleep on their other programs, which sweetens the pot for any deal: https://www.nature.com/articles/s41392-023-01589-z

User Image pcguy2 Posted - 3 days ago

$CKPT when is the FDA meeting happen? Didn't they say Q1?

User Image zed_rickel Posted - 3 days ago

$CKPT slow bleed to continue for the next 30-45 days until they announce resubmission?

User Image MayorofMNKD Posted - 3 days ago

$CKPT https://www.drvinayprasad.com/p/my-comments-at-fridays-fda-drug-advisory

User Image spinner14 Posted - 3 days ago

$CKPT TIme for an update to shareholders guys!!! We need results, updates, communication etc. Let's go, support your shareholders.

User Image MSBio Posted - 3 days ago

$CKPT time for some green, time to resolve the manufacturing issue

User Image ltfl Posted - 3 days ago

$CKPT curious is this the SWICH personal thoughts board?

User Image ltfl Posted - 3 days ago

$CKPT that 10% pre market really died quick huh?

User Image kiwiSurfer Posted - 3 days ago

$CKPT key 🔑 Support at $1.68. Will it hold? Doubt it I see $1 in 2 months.

User Image SWICH Posted - 3 days ago

$CKPT as a side note to my previous posts, the picture for the institutional ownership of CKPT's parent, FBIO, isn't as clear or particularly rosy. I can't be sure if the recent R/S for FBIO are reflected in these numbers, but in any case, the significant holdings of FBIO by some of the most manipulative hedge funds (CVI, Armistice, Nantahala, Susquehanna, etc.) is concerning. My experience investing in companies where these players held majority positions has not been very positive. The huge shifts in FBIO SP performance over the last few months would seem to support these concerns. How this will impact CKPT, if at all, remains to be seen.

Analyst Ratings
HC Wainwright & Co. Buy Mar 22, 24
B. Riley Securities Buy Dec 20, 23
HC Wainwright & Co. Buy Dec 19, 23
Lake Street Buy Aug 16, 23
Cantor Fitzgerald Overweight Aug 15, 23
Ladenburg Thalmann Buy Aug 15, 23
HC Wainwright & Co. Buy Aug 4, 23
Lake Street Buy May 30, 23
Ladenburg Thalmann Buy May 17, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
GRAY WILLIAM GARRETT Chief Financial Offi.. Chief Financial Officer Feb 01 Sell 1.95 4,115 8,024 147,259 02/02/24
Oliviero James F III CEO, President and D.. CEO, President and Director Feb 01 Sell 2.01 11,900 23,919 369,680 02/02/24
Oliviero James F III CEO, President and D.. CEO, President and Director Feb 27 Sell 4.83 11,031 53,280 144,090 03/03/23
GRAY WILLIAM GARRETT Chief Financial Offi.. Chief Financial Officer Feb 27 Sell 4.83 5,505 26,589 51,374 03/03/23
GRAY WILLIAM GARRETT Chief Financial Offi.. Chief Financial Officer Feb 01 Sell 4.79 3,154 15,108 49,379 02/03/23
Oliviero James F III CEO, President and D.. CEO, President and Director Feb 01 Sell 4.77 10,261 48,945 182,121 02/03/23
GRAY WILLIAM GARRETT Chief Financial Offi.. Chief Financial Officer Jan 10 Sell 6.749 1,858 12,540 52,533 01/12/23
Oliviero James F III CEO, President and D.. CEO, President and Director Jan 10 Sell 6.749 3,817 25,761 192,382 01/12/23
Oliviero James F III CEO, President and D.. CEO, President and Director Jun 17 Sell 1.1 276,000 303,600 2,562,003 07/01/22
Oliviero James F III CEO, President and D.. CEO, President and Director Jan 01 Sell 1.69 121,641 205,573 2,838,003 04/22/22
GRAY WILLIAM GARRETT Chief Financial Offi.. Chief Financial Officer Mar 10 Sell 1.893 38,197 72,307 543,910 03/11/22
GRAY WILLIAM GARRETT Chief Financial Offi.. Chief Financial Officer Jan 31 Sell 2.51 37,063 93,028 582,107 02/02/22